Artocarpesin acts on human platelet aggregation through inhibition of cyclic nucleotides and MAPKs

Abstract The cardiovascular diseases (CVDs) are becoming a critical threat to our lives in these years. It is now widely accepted that platelets play an important role disease as they have fundamental thrombosis. Therefore, many drugs or natural substances been developed treat CVDs. Cudrania tricuspidata regional plant containing various constituents, such xanthones, flavonoids, organic acids, and polysaccharides. has used East Asia ethnomedicine for the treatment of eczema, mumps, tuberculosis acute arthritis. we evaluated antiplatelet effects using artocarpesin isolated from C. tricuspidata. Confirmation function was made according following analyzes. Artocarpesin inhibited collagen-induced human platelet aggregation, calcium mobilization, glycoprotein IIb/IIIa activation thrombin-induced clot retraction through regulation associated signaling molecules. increased phosphorylation vasodilator-stimulated phosphoprotein (VASP) inositol 1, 4, 5-triphosphate receptor I (IP 3 RI). On other hand, cytosolic phospholipase A 2 (cPLA ), mitogen-activated protein kinases p38, JNK phosphoinositide 3-kinase (PI3K)/Akt decreased. Thus, study highlights inhibitory effect on activity thrombus formation, showing its potential value preventing platelet-induced disease.